I
Ingunn Holen
Researcher at University of Sheffield
Publications - 165
Citations - 8748
Ingunn Holen is an academic researcher from University of Sheffield. The author has contributed to research in topics: Breast cancer & Zoledronic acid. The author has an hindex of 52, co-authored 162 publications receiving 7809 citations. Previous affiliations of Ingunn Holen include Yorkshire Cancer Research & Weston Park Hospital.
Papers
More filters
Journal ArticleDOI
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer.
Suzanne A. Eccles,Eric O. Aboagye,Simak Ali,Annie S. Anderson,Jo Armes,Fedor Berditchevski,Jeremy P. Blaydes,Keith Brennan,Nicola J. Brown,Helen E. Bryant,Nigel J Bundred,Joy Burchell,Anna Campbell,Jason S. Carroll,Robert Clarke,Charlotte E. Coles,Gary Cook,Angela Cox,Nicola J. Curtin,Lodewijk V. Dekker,Isabel dos Santos Silva,Stephen W. Duffy,Douglas F. Easton,Diana Eccles,Dylan R. Edwards,Joanne Edwards,D. G. R. Evans,Deborah Fenlon,James M. Flanagan,Claire Foster,William M. Gallagher,Montserrat Garcia-Closas,Julia Margaret Wendy Gee,Andy J. Gescher,Vicky Goh,Ashley M. Groves,Amanda J. Harvey,Michelle Harvie,Bryan T. Hennessy,Stephen Edward Hiscox,Ingunn Holen,Sacha J Howell,Anthony Howell,Gill Hubbard,Nicholas J. Hulbert-Williams,Myra S. Hunter,Bharat Jasani,Louise J. Jones,Timothy J. Key,Cliona C. Kirwan,Anthony Kong,Ian Kunkler,Simon P. Langdon,Martin O. Leach,David J. Mann,John Marshall,Lesley Ann Martin,Stewart G. Martin,Jennifer E. Macdougall,David Miles,William R. Miller,Joanna R. Morris,Sue Moss,Paul B. Mullan,Rachel Natrajan,James P B O'Connor,Rosemary O'Connor,Carlo Palmieri,Paul D.P. Pharoah,Emad A. Rakha,Elizabeth Reed,Simon P. Robinson,Erik Sahai,John M. Saxton,Peter Schmid,Matthew J. Smalley,Valerie Speirs,Robert Stein,John Stingl,Charles H. Streuli,Andrew Tutt,Galina Velikova,Rosemary A. Walker,Christine J. Watson,Kaye J. Williams,Leonie S. Young,Alastair M. Thompson +86 more
TL;DR: With resources to conduct further high-quality targeted research focusing on the gaps identified, increased knowledge translating into improved clinical care should be achievable within five years.
Journal ArticleDOI
Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
Peter I. Croucher,C M Shipman,J M Lippitt,Mark Perry,Kewal Asosingh,Anja Hijzen,Alex C. Brabbs,Edwin J. R. van Beek,Ingunn Holen,Timothy M. Skerry,Colin R. Dunstan,G. Russell,Ben Van Camp,Karin Vanderkerken +13 more
TL;DR: The data suggest that the RANKL/RANK/OPG system may play a critical role in the development of osteolytic bone disease in multiple myeloma and that targeting this system may have therapeutic potential.
Journal ArticleDOI
Tumour macrophages as potential targets of bisphosphonates
Thea L. Rogers,Ingunn Holen +1 more
TL;DR: There is now a growing body of evidence, both from in vitro and in vivo models, showing that zoledronic acid can also target tumour cells to increase apoptotic cell death and decrease proliferation, migration and invasion, and that this effect is significantly enhanced in combination with chemotherapy agents.
Journal Article
Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.
TL;DR: A strong negative correlation was observed between levels of endogenously produced OPG in the medium and the capacity of TRAIL to induce apoptosis in cells that produced high levels of OPG, suggesting that prostate cancer-derived OPG may be an important survival factor in hormone-resistant prostate cancer cells.
Journal ArticleDOI
Zoledronic acid repolarizes tumour‐associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway
Marta Coscia,Elena Quaglino,Manuela Iezzi,Claudia Curcio,Francesca Pantaleoni,Chiara Riganti,Ingunn Holen,Hannu Mönkkönen,Mario Boccadoro,Guido Forni,Piero Musiani,Amalia Bosia,Federica Cavallo,Massimo Massaia +13 more
TL;DR: Data indicate that clinically achievable doses of ZA inhibit spontaneous mammary cancerogenesis by targeting the local microenvironment, as shown by a decreased tumour vascularization, a reduced number of tumour‐associated macrophages and their reverted polarization from M2 to M1 phenotype.